AU2009279086B2 - Parenteral composition comprising microspheres with a diameter between 10 and 20 microns - Google Patents

Parenteral composition comprising microspheres with a diameter between 10 and 20 microns Download PDF

Info

Publication number
AU2009279086B2
AU2009279086B2 AU2009279086A AU2009279086A AU2009279086B2 AU 2009279086 B2 AU2009279086 B2 AU 2009279086B2 AU 2009279086 A AU2009279086 A AU 2009279086A AU 2009279086 A AU2009279086 A AU 2009279086A AU 2009279086 B2 AU2009279086 B2 AU 2009279086B2
Authority
AU
Australia
Prior art keywords
cells
pharmaceutical composition
tissue
particles
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009279086A
Other languages
English (en)
Other versions
AU2009279086A1 (en
Inventor
Bernardo Nadal Ginard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coretherapix SL
Original Assignee
Coretherapix SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39846672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009279086(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coretherapix SL filed Critical Coretherapix SL
Publication of AU2009279086A1 publication Critical patent/AU2009279086A1/en
Application granted granted Critical
Publication of AU2009279086B2 publication Critical patent/AU2009279086B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009279086A 2008-08-05 2009-08-05 Parenteral composition comprising microspheres with a diameter between 10 and 20 microns Ceased AU2009279086B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0814302.6A GB0814302D0 (en) 2008-08-05 2008-08-05 Compounds and methods
GB0814302.6 2008-08-05
PCT/EP2009/060171 WO2010015665A2 (en) 2008-08-05 2009-08-05 Compounds and methods

Publications (2)

Publication Number Publication Date
AU2009279086A1 AU2009279086A1 (en) 2010-02-11
AU2009279086B2 true AU2009279086B2 (en) 2014-05-22

Family

ID=39846672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009279086A Ceased AU2009279086B2 (en) 2008-08-05 2009-08-05 Parenteral composition comprising microspheres with a diameter between 10 and 20 microns

Country Status (13)

Country Link
US (3) US20120195939A1 (enExample)
EP (1) EP2323626B1 (enExample)
JP (1) JP5623400B2 (enExample)
KR (1) KR101639827B1 (enExample)
CN (1) CN102170868A (enExample)
AU (1) AU2009279086B2 (enExample)
BR (1) BRPI0917571B1 (enExample)
CA (1) CA2732785C (enExample)
CL (1) CL2011000244A1 (enExample)
ES (1) ES2677005T3 (enExample)
GB (1) GB0814302D0 (enExample)
MX (1) MX2011001261A (enExample)
WO (1) WO2010015665A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US10195252B2 (en) 2012-08-03 2019-02-05 University of Pittsburgh—of the Commonwealth System of Higher Education Recruitment of mensenchymal cells using controlled release systems
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014066545A1 (en) * 2012-10-26 2014-05-01 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
US10526581B2 (en) * 2013-01-24 2020-01-07 Bernardo Nadal-Ginard Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
EP2759595B1 (en) * 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN104650333B (zh) * 2015-02-05 2016-08-24 浙江大学 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法
PL3264997T3 (pl) * 2015-03-02 2019-07-31 Accurate Medical Therapeutics Ltd. Cewniki z otworami bocznymi do modyfikowania i podawania zawiesin pacjentowi
JP6743041B2 (ja) 2015-03-30 2020-08-19 タリス バイオメディカル エルエルシー 上部尿路への薬剤の局所的な送達装置及び方法
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN109414266B (zh) 2016-05-04 2021-07-23 阿克瑞特医学治疗有限公司 具有狭缝状图案的栓塞微导管头部
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2017220611A1 (en) 2016-06-20 2017-12-28 Virbac Oral pharmaceutical composition comprising a pharmaceutically active agent, at least one cationic bioadhesive polymer and at least two anionic polymers
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN111447882B (zh) 2017-11-02 2024-05-24 阿克瑞特医学治疗有限公司 具有一体式过滤器的栓塞导管
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3737415A4 (en) * 2018-01-12 2021-06-30 President and Fellows of Harvard College COMPOSITIONS AND PROCEDURES RELATED TO MACROPHAGE AND / OR MONOCYTE WITH ATTACHED PARTICLES
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
BR112021023510A2 (pt) 2019-05-23 2022-01-18 Accurate Medical Therapeutics Ltd Cateter de embolização para distribuição livre de refluxo de microesferas.
EP4281044A1 (en) * 2021-01-22 2023-11-29 University of Connecticut Synthetic artificial stem cells (sasc)
CN121099998A (zh) * 2023-02-02 2025-12-09 银溪制药股份有限公司 使用igf-1嵌合蛋白的治疗方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350518A1 (en) * 1995-10-12 2003-10-08 Schering Aktiengesellschaft Prolonged release of GM-CSF
WO2004022000A2 (en) * 2002-09-05 2004-03-18 Ambrose Catherine G Antibiotic microspheres for treatment of infections and osteomyelitis
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
WO2009149106A2 (en) * 2008-06-03 2009-12-10 Abbott Cardiovascular Systems Inc. Microparticles for the treatment of disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
CN1175208A (zh) * 1994-12-16 1998-03-04 安达里斯有限公司 交联的微粒及其作为治疗载体的用途
CA2161863A1 (en) 1995-10-31 1997-05-01 Michael Vivian Sefton Angiogenic material and uses thereof
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
WO1998047532A1 (en) 1997-04-24 1998-10-29 Nycomed Imaging As Embolus therapy using insoluble microparticles or vesicles containing contrast agents
ATE220564T1 (de) 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
ATE233097T1 (de) * 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
JP2003516926A (ja) 1998-11-18 2003-05-20 ユニバーシティ オブ フロリダ コーティングされた薬物粒子及びその薬学的製剤を調製するための方法
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2003059375A1 (en) * 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US20070116768A1 (en) 2003-12-09 2007-05-24 Michael Chorny Sustained release preparations composed of biocompatible complex microparticles
WO2005094888A1 (ja) * 2004-03-31 2005-10-13 Two Cells Co. Ltd. 損傷組織の治療剤と治療方法
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
ES2273572B1 (es) * 2005-05-04 2008-04-01 Universidad De Sevilla Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas.
WO2007028053A2 (en) 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
KR100718329B1 (ko) 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US8506965B2 (en) * 2005-11-11 2013-08-13 Vascular Biosciences R-RAS activity in vascular regulation
CN101563097A (zh) * 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
ES2459743T3 (es) 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular
WO2008108736A1 (en) 2007-03-06 2008-09-12 Agency For Science, Technology And Research Particles for delivery of bioactive factors
EP2244697A1 (en) 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutic compositions
WO2009100128A1 (en) 2008-02-04 2009-08-13 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350518A1 (en) * 1995-10-12 2003-10-08 Schering Aktiengesellschaft Prolonged release of GM-CSF
WO2004022000A2 (en) * 2002-09-05 2004-03-18 Ambrose Catherine G Antibiotic microspheres for treatment of infections and osteomyelitis
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
WO2009149106A2 (en) * 2008-06-03 2009-12-10 Abbott Cardiovascular Systems Inc. Microparticles for the treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERKLAND C, et al. Journal of Controlled Release, (2001), Vol 73, pp 59-74 *
SANSDRAP P, et al. International Journal of Pharmaceutics, (1993), Vol 98 pp 157-164 *

Also Published As

Publication number Publication date
CN102170868A (zh) 2011-08-31
JP2011529946A (ja) 2011-12-15
AU2009279086A1 (en) 2010-02-11
CL2011000244A1 (es) 2011-07-15
KR20110051212A (ko) 2011-05-17
EP2323626B1 (en) 2018-04-11
WO2010015665A2 (en) 2010-02-11
BRPI0917571A2 (pt) 2020-08-11
US20130189321A1 (en) 2013-07-25
CA2732785A1 (en) 2010-02-11
KR101639827B1 (ko) 2016-07-14
CA2732785C (en) 2016-11-22
BRPI0917571B1 (pt) 2022-01-04
US20130315997A1 (en) 2013-11-28
US20120195939A1 (en) 2012-08-02
EP2323626A2 (en) 2011-05-25
ES2677005T3 (es) 2018-07-27
MX2011001261A (es) 2011-08-08
WO2010015665A3 (en) 2010-10-07
US8846099B2 (en) 2014-09-30
GB0814302D0 (en) 2008-10-01
JP5623400B2 (ja) 2014-11-12

Similar Documents

Publication Publication Date Title
AU2009279086B2 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
US20130309304A1 (en) Compounds and methods
US20240315979A1 (en) Purified exosome products, method of making, and methods of using
JP6881877B2 (ja) 細胞の封入および細胞集合体のための多層ヒドロゲルカプセル
Tobias et al. Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression
Ruvinov et al. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction
CN100393367C (zh) 可注射的交联聚合制剂及其应用
AU721726B2 (en) Immunoisolation
KR20140051161A (ko) 캡슐화된 치료제의 제조 방법 및 이의 용도
Choi et al. Injectable PLGA microspheres encapsulating WKYMVM peptide for neovascularization
Benoit et al. Microcapsules and microspheres for embolization and chemoembolization
US20050214377A1 (en) Microparticles for cell delivery
Zou Fabrication and Characterization of Double-Walled Microsphere as a Drug Delivery System for Stroke Treatment
Sanju et al. Micro and nanoparticles for the delivery of growth factors in diabetic wounds
Ho Local delivery of PACAP attenuates inflammation and promotes functional recovery in a mouse model of stroke injury
Sava The development of a hydrogel-based regenerative therapy for brain tissue repair and functional recovery following ischaemic stroke
CN101642559B (zh) 含微粉化人血管内皮抑制素的药物组合物
Onyekuru Electrohydrodynamic atomisation to fabricate model biotherapeutic particulates
KR20250162146A (ko) 라파마이신을 함유 약물 전달체가 접합된 줄기세포 및 이의 용도
Ruvinov et al. Instructive biomaterials for myocardial regeneration and repair
Yu Biomaterial-based tissue engineering approaches to repair myocardial infarction
Moore Microencapsulation of a Connexin-43 Mimetic Peptide as a Novel Wound Healing Agent in an Ocular Injury Model

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ NADAL GINARD, BERNARDO

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired